While Novavax has some positives, it is not a good candidate for new money. Novavax's two marquee programs, RSV F for maternal vaccination and NanoFlu are not doing particularly well, as they are getting delayed.
RSV F for maternal vaccination is now in Phase 3, but many investors are wondering if it's a viable drug. Even if Novavax successfully meets the development challenges, it may face strong competition from other biotech companies.
One possibility for Novovax is to be bought out, in which case the stock may be underpriced.
finstead.com/bite/Novavax -NVAX-stock-forecast-prediction-august-4-2018
RSV F for maternal vaccination is now in Phase 3, but many investors are wondering if it's a viable drug. Even if Novavax successfully meets the development challenges, it may face strong competition from other biotech companies.
One possibility for Novovax is to be bought out, in which case the stock may be underpriced.
finstead.com/bite/Novavax -NVAX-stock-forecast-prediction-august-4-2018
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。